Oxycodone’s elimination half-life in a healthy adult is roughly three to four hours, meaning half the drug is cleared from your blood in that window. But “how long it stays in your system” depends heavily on what you mean by “system” and who is asking. A standard urine drug test can pick up oxycodone or its breakdown products for about 30 to 40 hours after a single dose, while a hair test can flag use from months earlier. The real answer is shaped by your age, liver and kidney health, genetics, the formulation you took, and what other medications are in the mix.
How Your Body Breaks Down Oxycodone
Oxycodone is processed primarily in the liver by two enzyme families. The bulk of the work is done by CYP3A4, which converts oxycodone into noroxycodone, a relatively weak metabolite. A smaller but clinically meaningful pathway runs through CYP2D6, producing oxymorphone, a metabolite with roughly 40 to 60 times greater affinity for the mu-opioid receptor than oxycodone itself.1PubMed. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation Only a small fraction of the original dose leaves the body unchanged in urine. Most of what eventually shows up in a drug test is one of these metabolites, not the parent drug.
This matters for detection because drug tests look for different things. Some screen only for oxycodone itself, others look for its metabolites. Understanding which pathway dominates in your body and how efficiently those enzymes work gives you a much better sense of how long traces will remain detectable.
Immediate-Release Versus Extended-Release Formulations
Oxycodone comes in two main oral forms, and the formulation you take changes how long the drug lingers. Immediate-release (IR) versions are absorbed quickly with a straightforward absorption profile, while controlled-release (CR) tablets have a two-phase absorption pattern. About 38% of the dose absorbs rapidly, with an absorption half-life of around 37 minutes, and the remaining 62% absorbs much more slowly, with an absorption half-life of roughly six hours.2PubMed Central. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone This design allows twice-daily dosing instead of the every-four-to-six-hour schedule typical of IR products.
The practical consequence is that extended-release oxycodone feeds into your bloodstream over a much longer period, and the slower drug delivery actually changes how quickly your body clears it. Research has shown that the slower release rate reduces total body clearance, meaning the drug effectively hangs around longer than you would predict from the half-life of an IR dose alone.3PubMed Central. Slow drug delivery decreased total body clearance and altered bioavailability of immediate- and controlled-release oxycodone formulations If you are taking an extended-release product, expect oxycodone to be detectable in your body for somewhat longer than the timelines that apply to IR versions.
Detection Windows by Test Type
Urine
Urine testing is by far the most common way oxycodone use is screened, whether in pain management clinics, workplace testing, or legal settings. In a controlled study where healthy adults received a single 20 mg oral dose, oxycodone appeared in urine within two hours. Peak concentrations of oxycodone and its metabolites occurred between three and 19 hours. At a cutoff concentration of 50 ng/mL, oxycodone itself was detectable for about 30 hours, while noroxycodone and oxymorphone remained detectable for around 40 hours.4Journal of Analytical Toxicology. Prescription Opioids. I. Metabolism and Excretion Patterns of Oxycodone in Urine Following Controlled Single Dose Administration
There is an important nuance here for anyone interpreting results. Oxycodone concentrations in urine drop off faster than its metabolites, so some later urine specimens contained no detectable oxycodone at all but still tested positive for noroxycodone. This is actually useful for test interpretation because finding noroxycodone confirms oxycodone was the original drug taken, rather than oxymorphone having been ingested directly.4Journal of Analytical Toxicology. Prescription Opioids. I. Metabolism and Excretion Patterns of Oxycodone in Urine Following Controlled Single Dose Administration Keep in mind that these numbers come from a single-dose study in healthy people. Chronic use, higher doses, and impaired organ function will extend these windows.
Saliva
Oral fluid testing is gaining popularity because collection is straightforward and harder to tamper with than urine. Oxycodone concentrates in saliva at substantially higher levels than in blood. In a study of patients on chronic oxycodone therapy, the geometric mean oxycodone concentration in saliva was 860 ng/mL, with an enormous range stretching from 1.5 to over 8.6 million ng/mL across specimens.5Journal of Opioid Management. Monitoring oxycodone use in patients with chronic pain: Analysis of oxycodone and metabolite excretion in saliva and urine General estimates for detection in saliva range from one to four days, though the wide variability in saliva concentrations means individual results can differ dramatically. The high saliva-to-plasma ratio makes this a sensitive testing medium, but the wild spread in concentrations also makes precise timing estimates less reliable than urine data.
Hair
Hair testing offers the longest detection window of any method, potentially reaching back 90 days or more depending on hair length. As the drug circulates in your bloodstream, it gets incorporated into the keratin matrix of growing hair, and the amount deposited is generally dose-responsive: higher oxycodone intake produces higher concentrations in the hair shaft.6Journal of Analytical Toxicology. Opioid hair concentrations using retrospective prescription data from a United States workplace testing population
Hair testing for oxycodone has a significant limitation, though. The oxymorphone metabolite, which labs typically look for to confirm that oxycodone was actually ingested rather than externally deposited, is rarely detected. In a review of 466 oxycodone-positive hair specimens, only about 10% also contained detectable oxymorphone at the standard 100 pg/mg cutoff. When oxycodone was present at or below the median concentration, that number dropped to barely 1%.7Journal of Analytical Toxicology. The Disposition of Oxycodone and Metabolite in Human Hair This has real implications: someone could argue that a positive oxycodone result in hair represents environmental contamination rather than ingestion, and the absence of metabolite makes it harder to refute. More sensitive assays are needed before hair testing for oxycodone can match the interpretive confidence of urine testing.
Why Age Has Such a Large Effect
Age is one of the strongest predictors of how long oxycodone stays in your body, and the effect is bigger than most people realize. When researchers compared the pharmacokinetics of a 10 mg oral oxycodone dose across age groups, patients in their 70s and 80s had 50 to 80% higher overall exposure to the drug and roughly double the plasma concentration at 12 hours compared to adults in their 20s and 30s.8PubMed. Plasma concentrations of oral oxycodone are greatly increased in the elderly In the oldest group studied (over 80), total body clearance was about a third lower than in younger adults, and oxycodone concentrations from eight hours onward were more than twice as high.9PubMed. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups
Population pharmacokinetic modeling has confirmed this pattern, showing that elimination clearance drops steadily with advancing age and that the half-life increases accordingly.10British Journal of Anaesthesia. Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study For an older adult, the practical takeaway is that a standard dose will produce higher blood levels, last longer, and take longer to clear. This is one reason clinicians are advised to start with lower doses and titrate carefully in elderly patients.
Liver Disease and Kidney Impairment
Because the liver does nearly all of the metabolic work on oxycodone, liver disease has a dramatic effect on clearance. In patients with cirrhosis awaiting liver transplantation, the median elimination half-life of oxycodone was about 14 hours, roughly four times the typical value. After transplantation and restoration of normal liver function, the half-life dropped back to about 3.4 hours and clearance increased roughly fourfold.11PubMed. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation A half-life of 14 hours means that oxycodone would remain in the bloodstream at meaningful concentrations for well over two days after a single dose, and the risk of accumulation with repeated dosing increases steeply.
Kidney disease also slows elimination, though by a different mechanism. In patients with end-stage renal failure, the elimination half-life is prolonged due to increased volume of distribution and reduced clearance, and plasma concentrations of the noroxycodone metabolite are notably higher.12PubMed. Opioids in renal failure and dialysis patients 13Journal of Clinical Anesthesia. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation Smaller quantities of oxycodone and its metabolites are excreted in the urine when the kidneys are failing, which means both the drug and its breakdown products accumulate. Guidelines generally suggest that oxycodone can be used with caution in kidney disease but requires close monitoring, and it is considered a better option than morphine in that population.12PubMed. Opioids in renal failure and dialysis patients
Your Genes Change the Timeline
Not everyone metabolizes oxycodone at the same speed, and a large part of that variation comes down to genetics. The CYP2D6 enzyme exists in several genetic variants, broadly grouped as poor metabolizers, normal metabolizers, and ultrarapid metabolizers. Research using a large clinical database of urine drug tests found a 6.9-fold difference in the oxymorphone-to-oxycodone ratio between ultrarapid and poor metabolizers of CYP2D6.14PubMed. Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests Poor metabolizers produced so little oxymorphone that their specimens were about five times more likely to test negative for it entirely.
In a study of postoperative patients, CYP2D6 poor metabolizers had the lowest oxymorphone levels and actually consumed more oxycodone over the first 12 hours, suggesting they got less analgesic effect per dose because they were not efficiently converting oxycodone to its more potent metabolite.15PLoS ONE. CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative Patients Variation in CYP2C19 also plays a role, though the effect is smaller, producing about a 1.6-fold difference in metabolite ratios between ultrarapid and poor metabolizers.14PubMed. Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests If you are a poor metabolizer, oxycodone itself will persist longer in your system because the enzyme that should be converting it to oxymorphone is working slowly or barely at all.
Drug Interactions That Change Clearance
Because oxycodone relies on CYP3A4 and CYP2D6 for breakdown, other medications that compete for or block those enzymes can substantially alter how long oxycodone stays active. Inhibiting CYP3A4 alone raises oxycodone levels, and blocking both CYP3A4 and CYP2D6 at the same time produces even larger increases. Common CYP3A4 inhibitors include certain antifungals, some antibiotics, and grapefruit juice in large quantities. CYP2D6 inhibitors include several antidepressants, some antihistamines, and certain heart rhythm medications.16PubMed. Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications
The flip side is also clinically relevant. Enzyme inducers like rifampicin, carbamazepine, and St. John’s wort speed up oxycodone metabolism so much that blood levels can drop below therapeutic concentrations, potentially leaving pain uncontrolled.16PubMed. Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications This also means oxycodone will clear your system faster if you are taking one of these inducers, which could matter if you need detectable levels for a pain management compliance test. Anyone starting or stopping a medication that affects these enzymes should be aware that their effective oxycodone dose and clearance timeline may shift.
Body Composition and Distribution
Oxycodone distributes widely through body tissues, and your body composition influences how much tissue there is for the drug to distribute into. Lean body mass has been identified as a significant covariate for the volume of distribution of oxycodone.17PubMed Central. Population pharmacokinetics and analgesic potency of oxycodone A larger volume of distribution generally means the drug spreads more broadly through your tissues, which can extend the total time needed for complete elimination even if the enzymatic clearance rate stays the same. This is one reason why two people of the same age and liver function might have different detection windows.
When Screening Tests Get It Wrong
Most initial drug screens use immunoassay technology, which is fast and relatively cheap but imperfect. Immunoassays work by detecting molecules that look structurally similar to the target drug, and that structural similarity can produce false positives. In an evaluation of immunoassay performance for opioid detection in urine, sensitivity for oxycodone was high (96 to 100%), but false-positive results occurred in about 14% of specimens across multiple opioid classes when accounting for all immunoassay panels tested.18The Journal of Applied Laboratory Medicine. Evaluation of Immunoassay Performance for the Detection of Opioids in Urine
This is why a positive immunoassay screen is never the final word. Confirmatory testing, typically by liquid chromatography-tandem mass spectrometry, is far more specific and can distinguish oxycodone from structurally similar opioids. If you have a legitimate prescription and test positive on a screen, the confirmatory test will identify the specific drug and its metabolites, which is also how labs can tell whether someone took oxycodone versus oxymorphone directly. If you are facing a high-stakes test and take any opioid medication, make sure the testing facility knows about your prescriptions before the screen, not after a positive result comes back.
Oxycodone Transfer Into Breast Milk
Oxycodone is commonly prescribed after cesarean delivery, and the question of how long it persists in breast milk has received close attention. The drug does transfer into milk, and it does so at unexpectedly high concentrations. Two independent studies found a median milk-to-plasma ratio of about 3.2 to 1, meaning breast milk contained roughly three times the concentration of oxycodone found in maternal blood.19PubMed. Oxycodone as a component of multimodal analgesia for lactating mothers after Caesarean section: relationships between maternal plasma, breast milk and neonatal plasma levels 20PubMed. Breast milk oxycodone concentrations in mothers given oxycodone for post-Caesarean delivery pain management There was also evidence that oxycodone persisted in some mothers’ breast milk even after it had largely cleared from their plasma, suggesting a lag in milk clearance.
The reassuring finding is that even in simulated worst-case neonatal exposure scenarios, the estimated weight-adjusted infant dose remained below 10% of the maternal dose, which is the general threshold used to gauge safety during breastfeeding.20PubMed. Breast milk oxycodone concentrations in mothers given oxycodone for post-Caesarean delivery pain management Still, levels as high as 168 ng/mL were measured in some breast milk samples, and oxycodone was detected in the plasma of at least one infant.19PubMed. Oxycodone as a component of multimodal analgesia for lactating mothers after Caesarean section: relationships between maternal plasma, breast milk and neonatal plasma levels For nursing mothers, the key point is that oxycodone clears from milk more slowly than from blood, and short-term use at the lowest effective dose is the approach recommended by most obstetric guidelines.
Neonatal and Infant Clearance
Newborns and very young infants process oxycodone differently from adults. Their liver enzyme systems are still maturing, which changes both the speed of metabolism and the metabolite profile. In neonates and infants, noroxycodone was the major metabolite found in both plasma and urine, consistent with the CYP3A4 pathway being relatively more active even in immature livers.21PubMed Central. Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine The CYP2D6 pathway, which produces the more potent oxymorphone metabolite, matures at a different rate, so the balance of metabolites in a newborn exposed to oxycodone through breast milk or direct administration will look different from an adult’s profile. Clinicians monitoring exposed infants watch for signs of sedation and respiratory depression rather than relying solely on plasma levels, because the relationship between drug concentration and effect is less predictable in this age group.